Skip to main content

Market Overview

Recap: Recro Pharma Q1 Earnings


Shares of Recro Pharma (NASDAQ:REPH) fell 7.4% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were down 230.00% year over year to ($0.33), which missed the estimate of ($0.03).

Revenue of $21,777,000 lower by 13.12% from the same period last year, which beat the estimate of $19,450,000.


Recro Pharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Recent Stock Performance

Company's 52-week high was at $19.21

Company's 52-week low was at $6.10

Price action over last quarter: down 18.09%

Company Description

Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.


Related Articles (REPH)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at